Zimmer Biomet CEO Ivan Tornos said he anticipates ASCs to be a major support for growing orthopedic case volumes during the Barclays 27th Annual Global Healthcare Conference.
“That is a huge tailwind for volumes,” he said, according to a March 13 investing.com transcript. “Before, you had to go get your case done in a hospital setting. Now people are going to ASCs, go on a Saturday morning and leave the same night.”
Mr. Tornos also said he expected to see 40% to 60% of all surgical cases going to the ASC within three to five years.
Zimmer Biomet has made important steps in the ASC space in the last year. The company partnered with CBRE to support outpatient orthopedics, and its acquisition of Paragon 28 aims to grow its presence in ASCs.
Zimmer Biomet also debuted its ZBX ASC program, which provides support to facilities wanting to incorporate outpatient orthopedics.
